Integra Lifesciences (NASDAQ:IART) issued its quarterly earnings results on Thursday. The life sciences company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.03, MarketWatch Earnings reports. The firm had revenue of $383.30 million during the quarter, compared to the consensus estimate of $382.33 million. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. Integra Lifesciences’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.64 earnings per share. Integra Lifesciences updated its FY 2019 guidance to $2.65-2.72 EPS and its FY19 guidance to $2.65-$2.72 EPS.
Shares of Integra Lifesciences stock traded up $3.54 on Thursday, reaching $55.47. 26,009 shares of the company were exchanged, compared to its average volume of 356,899. The company has a current ratio of 3.20, a quick ratio of 2.08 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $4.36 billion, a price-to-earnings ratio of 28.61, a PEG ratio of 1.43 and a beta of 0.89. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $67.50.
A number of brokerages recently commented on IART. Cantor Fitzgerald reissued a “hold” rating and issued a $50.00 price target on shares of Integra Lifesciences in a report on Thursday. BidaskClub upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Monday. ValuEngine upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 13th. Finally, SunTrust Banks started coverage on Integra Lifesciences in a research note on Thursday, January 3rd. They set a “buy” rating and a $56.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $61.69.
Several institutional investors have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund grew its holdings in Integra Lifesciences by 4,410.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock worth $28,000 after buying an additional 1,226,245 shares in the last quarter. Enlightenment Research LLC bought a new position in Integra Lifesciences in the 4th quarter worth approximately $32,000. Legacy Financial Advisors Inc. bought a new position in Integra Lifesciences in the 4th quarter worth approximately $33,000. Fort L.P. bought a new position in Integra Lifesciences in the 4th quarter worth approximately $34,000. Finally, Executive Wealth Management LLC bought a new position in Integra Lifesciences in the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 85.45% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Integra Lifesciences (IART) Announces Earnings Results, Beats Estimates By $0.03 EPS” was first reported by Zolmax and is owned by of Zolmax. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://zolmax.com/investing/integra-lifesciences-iart-announces-earnings-results-beats-estimates-by-0-03-eps/2917440.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.